A Novel Group of Promiscuous Podophages Infecting Diverse Gammaproteobacteria from River Communities Exhibits Dynamic Intergenus Host Adaptation

Cazares, Daniel; Cazares, Adrián; Figueroa, Wendy; Guarneros, Gabriel; Edwards, Robert A.; Vinuesa, Pablo

doi:10.1128/msystems.00773-20

Cited by 26 publications

(23 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Their host range is narrow, rarely expanding beyond the species level (although broad host range phages may be more common than current surveys suggest). 64 For tailed phages, such as E. coli T4, the infection cycle is well characterized. When a phage encounters a host, its tail fibers bind to a cognate receptor on the cell surface, and the phage injects its DNA into the cell, hijacking the host replication machinery to produce new phages.…”

Section: Bacteriophagesmentioning

confidence: 99%

See 1 more Smart Citation

How to kill Pseudomonas—emerging therapies for a challenging pathogen

Yaeger

Coles

Chan

et al. 2021

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

As the number of effective antibiotics dwindled, antibiotic resistance (AR) became a pressing concern. Some Pseudomonas aeruginosa isolates are resistant to all available antibiotics. In this review, we identify the mechanisms that P. aeruginosa uses to evade antibiotics, including intrinsic, acquired, and adaptive resistance. Our review summarizes many different approaches to overcome resistance. Antimicrobial peptides have potential as therapeutics with low levels of resistance evolution. Rationally designed bacteriophage therapy can circumvent and direct evolution of AR and virulence. Vaccines and monoclonal antibodies are highlighted as immune-based treatments targeting specific P. aeruginosa antigens. This review also identifies promising drug combinations, antivirulence therapies, and considerations for new antipseudomonal discovery. Finally, we provide an update on the clinical pipeline for antipseudomonal therapies and recommend future avenues for research.

show abstract

Section: Bacteriophagesmentioning

confidence: 99%

“…Phages are viruses that infect bacteria. Their host range is narrow, rarely expanding beyond the species level (although broad host range phages may be more common than current surveys suggest) 64 . For tailed phages, such as E. coli T4, the infection cycle is well characterized.…”

Section: Emerging Therapeutics For the Treatment Of P Aeruginosa Infectionsmentioning

confidence: 99%

How to kill Pseudomonas—emerging therapies for a challenging pathogen

Yaeger

Coles

Chan

et al. 2021

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…Phages are typically thought to infect a single species or closely related genera of bacteria. However, the recent identification of promiscuous phages able to infect several different bacterial genera was described, suggesting that phage populations may be capable of infecting a much broader repertoire of bacteria [60]. In order to infect bacteria, the phage must first bind.…”

Section: Phage and Mucinmentioning

confidence: 99%

Exploring Mucin as Adjunct to Phage Therapy

Carroll‐Portillo

Lin

2021

Microorganisms

View full text Add to dashboard Cite

Conventional phage therapy using bacteriophages (phages) for specific targeting of pathogenic bacteria is not always useful as a therapeutic for gastrointestinal (GI) dysfunction. Complex dysbiotic GI disorders such as small intestinal bowel overgrowth (SIBO), ulcerative colitis (UC), or Crohn’s disease (CD) are even more difficult to treat as these conditions have shifts in multiple populations of bacteria within the microbiome. Such community-level structural changes in the gut microbiota may require an alternative to conventional phage therapy such as fecal virome transfer or a phage cocktail capable of targeting multiple bacterial species. Additionally, manipulation of the GI microenvironment may enhance beneficial bacteria–phage interactions during treatment. Mucin, produced along the entire length of the GI tract to protect the underlying mucosa, is a prominent contributor to the GI microenvironment and may facilitate bacteria–phage interactions in multiple ways, potentially serving as an adjunct during phage therapy. In this review, we will describe what is known about the role of mucin within the GI tract and how its facilitation of bacteria–phage interactions should be considered in any effort directed at optimizing effectiveness of a phage therapy for gastrointestinal dysbiosis.

show abstract

“…the number of phage offspring resulting from infection) (Hyman & Abedon, 2010). Depending on the molecular mechanisms of infection, the host range of a bacteriophage can therefore be specific to a single genotype within a bacterial species, whereas other bacteriophages can infect bacteria of different genera (Cazares et al., 2021; Koskella & Meaden, 2013; Meaden & Koskella, 2013). From the point of view of the bacteriophage, the hosts are seen in terms of the presence/absence of multiple molecular mechanisms (e.g.…”

Section: Bacteriophage Versus Antibiotic Potentialitiesmentioning

confidence: 99%

Evolutionary biology and development model of medicines: A necessary ‘pas de deux’ for future successful bacteriophage therapy

Froissart

Brives

2021

J of Evolutionary Biology

View full text Add to dashboard Cite

enomics at the beginning of the 21st century, produced an unprecedented wealth of knowledge and data on microbes. Medical microbiology has greatly contributed to the increase in the life expectancy of humans and their domestic animals, partly due to the discovery and use of antibacterial chemical molecules (hereafter referred as antibiotics) as early as the first half of the 20th century. The discovery of antibiotics, their massive production from the 1940s onwards, and their widespread use in the second half of the 20th

show abstract

A Novel Group of Promiscuous Podophages Infecting Diverse Gammaproteobacteria from River Communities Exhibits Dynamic Intergenus Host Adaptation

Cited by 26 publications

References 52 publications

How to kill Pseudomonas—emerging therapies for a challenging pathogen

How to kill Pseudomonas—emerging therapies for a challenging pathogen

Exploring Mucin as Adjunct to Phage Therapy

Evolutionary biology and development model of medicines: A necessary ‘pas de deux’ for future successful bacteriophage therapy

Contact Info

Product

Resources

About